These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15770467)

  • 1. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
    Ahrén B
    Diabetologia; 2005 Apr; 48(4):605-7. PubMed ID: 15770467
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
    Mest HJ; Mentlein R
    Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
    Holst JJ; Deacon CF
    Diabetologia; 2005 Apr; 48(4):612-5. PubMed ID: 15759106
    [No Abstract]   [Full Text] [Related]  

  • 4. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
    Nauck MA; El-Ouaghlidi A
    Diabetologia; 2005 Apr; 48(4):608-11. PubMed ID: 15761719
    [No Abstract]   [Full Text] [Related]  

  • 5. Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
    Demuth HU; Hinke SA; Pederson RA; McIntosh CH
    Biochem Biophys Res Commun; 2002 Aug; 296(2):229-32. PubMed ID: 12163006
    [No Abstract]   [Full Text] [Related]  

  • 6. Sitagliptin (Januvia) for type 2 diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties.
    Ahrén B
    Expert Opin Investig Drugs; 2006 Apr; 15(4):431-42. PubMed ID: 16548792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
    Deacon CF
    Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut hormones and related concepts.
    Bloomgarden ZT
    Diabetes Care; 2006 Oct; 29(10):2319-24. PubMed ID: 17003315
    [No Abstract]   [Full Text] [Related]  

  • 14. Emerging treatments for patients with type 2 diabetes.
    Haines ST
    Diabetes Educ; 2007; 33 Suppl 5():105S-10S. PubMed ID: 17548897
    [No Abstract]   [Full Text] [Related]  

  • 15. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding new treatments for diabetes--how many, how fast... how good?
    Nathan DM
    N Engl J Med; 2007 Feb; 356(5):437-40. PubMed ID: 17267901
    [No Abstract]   [Full Text] [Related]  

  • 19. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors.
    Siminerio L
    Diabetes Educ; 2007; 33 Suppl 5():111S-3S. PubMed ID: 17548898
    [No Abstract]   [Full Text] [Related]  

  • 20. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
    Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.